These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32854982)

  • 1. Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    Genescà J
    J Hepatol; 2020 Nov; 73(5):1289-1290. PubMed ID: 32854982
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    Charette JH; Burak KW; Coffin CS; Congly SE; Lee SS; Israelson H; Williams S; Sadler M; Borman MA; Aspinall AI; Swain MG; Shaheen AA
    J Hepatol; 2020 Nov; 73(5):1287-1289. PubMed ID: 32883554
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    Nakatsuka T; Tateishi R; Nakagomi R; Minami T; Koike K
    J Hepatol; 2022 Aug; 77(2):569-571. PubMed ID: 35288188
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment.
    Kim JH; Kim MN; Han KH; Kim SU
    Liver Int; 2015 Apr; 35(4):1103-15. PubMed ID: 24976523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient elastography in DAA era. Relation between post-SVR LSM and histology.
    Martínez-Campreciós J; Bonis Puig S; Pons Delgado M; Salcedo Allende MT; Mínguez Rosique B; Genescà Ferrer J
    J Viral Hepat; 2020 Apr; 27(4):453-455. PubMed ID: 31816146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
    Blanco JR; Rivero-Juárez A
    Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'.
    Semmler G; Mandorfer M
    J Hepatol; 2022 Aug; 77(2):571-572. PubMed ID: 35526785
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs.
    Ridziauskas M; Zablockienė B; Jančorienė L; Samuilis A; Zablockis R; Jackevičiūtė A
    Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652777
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.
    Sánchez-Azofra M; Fernández I; García-Buey ML; Domínguez-Domínguez L; Fernández-Rodríguez CM; Mancebo A; Bonet L; Ryan P; Gea F; Díaz-Sánchez A; García-Mayor M; Martín-Carbonero L; Castillo P; Manzano ML; González-Moreno L; Pulido F; Gutiérrez ML; Moreno JM; García-Amengual IM; Cuevas G; Guerrero A; Rivero-Fernández M; Portales ME; Montes ML; Olveira A
    Liver Int; 2021 Dec; 41(12):2885-2891. PubMed ID: 34392590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
    Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
    J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
    Nishiguchi S; Kubo S; Shiomi S
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography.
    Higuchi M; Tamaki N; Kurosaki M; Watakabe K; Osawa L; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Izumi N
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2616-2618. PubMed ID: 30502507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment.
    Nakagomi R; Tateishi R; Masuzaki R; Soroida Y; Iwai T; Kondo M; Fujiwara N; Sato M; Minami T; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Kondo Y; Tanaka Y; Otsuka M; Kato N; Moriya K; Ikeda H; Koike K
    J Gastroenterol Hepatol; 2019 May; 34(5):921-928. PubMed ID: 30393960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis.
    Abadía M; Montes ML; Ponce D; Froilán C; Romero M; Poza J; Hernández T; Fernández-Martos R; Olveira A;
    World J Gastroenterol; 2019 Jun; 25(21):2665-2674. PubMed ID: 31210717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment.
    Lin MT; Chang KC; Yen YH; Tsai MC; Chen CH; Wang JH; Hsiao CC; Chiu YH; Hu TH
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):621-628. PubMed ID: 32718890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hepatocellular carcinoma in patients with chronic hepatitis c infection and stage 3 fibrosis after sustained virological response.
    Olveira Martín A; García Montes ML; Sanchez-Azofra M
    Rev Esp Enferm Dig; 2022 Jun; 114(6):309-311. PubMed ID: 35510319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patients with HCV advanced chronic liver disease after oral antivirals".
    Genescà J
    J Hepatol; 2020 Aug; 73(2):472-473. PubMed ID: 32493575
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.